ArticleCancer medicine2022
Is young-onset esophageal adenocarcinoma increasing in Japan? An analysis of population-based cancer registries.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- A steadily increasing trend in the incidence of esophageal adenocarcinoma in Akita Prefecture, Japan, through 2024.Journal of gastroenterology · 2026Article
- Adenocarcinoma of the esophagogastric junction: characteristics of female patients and young adult patients based on a 12-year retrospective and prospective multicenter clinicoepidemiological cohort study in Japan.BMC gastroenterology · 2024Article
- A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands.Journal of cancer research and clinical oncology · 2023Article
- Article
- Anti-reflux versus conventional self-expanding metal stents in the palliation of esophageal cancer: A systematic review and meta-analysis.Endoscopy international open · 2022Review
- Is young-onset esophageal adenocarcinoma increasing in Japan? An analysis of population-based cancer registries.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile esophageal squamous cell carcinoma (ESCC) is the predominant histological type in Japan, concern has been expressed over an increase in the proportion of esophageal adenocarcinoma (EAC), especially in middle-aged populations. This study aimed to assess long-term trends in esophageal cancer incidence by histological type.
methodsWe used data from three population-based cancer registries in Japan with 10,642 esophageal cancer cases diagnosed between 1993 and 2014. The multiple imputation approach was used to impute a specific histological type (ESCC, EAC, and others) for cases with "Unknown" or missing status. We calculated the age-standardized incidence rates by histological type from 1993 to 2014 and fitted age-period-cohort models to estimate the annual percent changes (APCs) and adjusted incidence rate ratios (IRRs).
resultsAfter imputation of missing data, the largest mean APC increase was seen in the incidence of EAC in men aged 40-49 years (7.1%) followed by those aged 50-59 years (5.5%). The age-period-cohort analysis showed that men who were born in the 1960s and later were more likely to develop EAC relative to men who were born in 1950-1959 (1960-1969 cohort, IRR: 1.42; 1970-1974 cohort, IRR: 2.23), with a period effect indicating a constant increase after 2003. For women, no significant trend in EAC incidence was observed.
conclusionsThe incidence of EAC has increased more prominently compared with that of ESCC, especially in men aged 40-59 years, suggesting the impact of increasing obesity in men and a reduction in H. pylori prevalence in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.